Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000284600, termed "novel transcript, antisense to MYT1L," is a long non-coding RNA located on chromosome 2, transcribed in the direction opposite to the MYT1L gene[1][4]. As an antisense lncRNA, it does not code for a protein but overlaps with the MYT1L locus, allowing it to potentially influence the expression of the MYT1L gene through various mechanisms common to antisense transcripts. These mechanisms may include transcriptional interference, RNA masking, double-stranded RNA-mediated effects (like RNA interference), and influencing chromatin state, all of which can affect the production, processing, and stability of the corresponding sense transcript[2][5]. While antisense lncRNAs as a class are functionally diverse, the precise biological role, disease association, or therapeutic relevance of this particular transcript remains uncharacterized.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to MYT1L.